[go: up one dir, main page]

AR094502A1 - Pirazoles sustituidos en posicion 3 y usos de los mismos - Google Patents

Pirazoles sustituidos en posicion 3 y usos de los mismos

Info

Publication number
AR094502A1
AR094502A1 ARP140100161A AR094502A1 AR 094502 A1 AR094502 A1 AR 094502A1 AR P140100161 A ARP140100161 A AR P140100161A AR 094502 A1 AR094502 A1 AR 094502A1
Authority
AR
Argentina
Prior art keywords
pirazoles
replaced
same
pirazoles replaced
Prior art date
Application number
Other languages
English (en)
Inventor
Anthony Estrada
Wen Liu
Snahel Patel
Michael Siu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR094502A1 publication Critical patent/AR094502A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
ARP140100161 2013-01-18 2014-02-17 Pirazoles sustituidos en posicion 3 y usos de los mismos AR094502A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361754501P 2013-01-18 2013-01-18

Publications (1)

Publication Number Publication Date
AR094502A1 true AR094502A1 (es) 2015-08-05

Family

ID=50031308

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100161 AR094502A1 (es) 2013-01-18 2014-02-17 Pirazoles sustituidos en posicion 3 y usos de los mismos

Country Status (12)

Country Link
US (2) US9550777B2 (es)
EP (1) EP2945938B1 (es)
JP (1) JP6199991B2 (es)
KR (1) KR101701663B1 (es)
CN (1) CN104918934B (es)
AR (1) AR094502A1 (es)
BR (1) BR112015016395A2 (es)
CA (1) CA2896187A1 (es)
MX (1) MX2015009270A (es)
RU (1) RU2015131314A (es)
TW (1) TWI498325B (es)
WO (1) WO2014111496A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871695A1 (en) * 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
BR112015022340A2 (pt) 2013-03-15 2017-07-18 Verseon Corp método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
KR20160002850A (ko) 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
MX2016008110A (es) * 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
RU2017131562A (ru) * 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
JP2019528319A (ja) * 2016-08-29 2019-10-10 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 疾患の処置のための二重ロイシンジッパー（ｄｌｋ）キナーゼの阻害薬
CA3031585A1 (en) 2016-09-09 2018-03-15 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
US20180085104A1 (en) * 2016-09-27 2018-03-29 Arthrex, Inc. Arthroscopic retracting probe
JP7128816B2 (ja) 2016-12-08 2022-08-31 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤
US10550726B2 (en) * 2017-01-30 2020-02-04 General Electric Company Turbine spider frame with additive core
PT3652178T (pt) 2017-07-14 2024-03-18 H Hoffnabb La Roche Ag Compostos bicíclicos de cetona e métodos de utilização dos mesmos
MX2020003439A (es) 2017-10-11 2020-07-29 Hoffmann La Roche Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
CR20200168A (es) 2017-10-31 2020-07-12 Hoffmann La Roche Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
TW201927738A (zh) * 2017-12-14 2019-07-16 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
CN108282723B (zh) * 2017-12-21 2020-06-16 瑞声科技(新加坡)有限公司 扬声器箱
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
WO2020061377A1 (en) * 2018-09-19 2020-03-26 Genentech, Inc. Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
WO2020146615A1 (en) 2019-01-11 2020-07-16 Genentech, Inc. Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
US11560366B2 (en) 2019-10-21 2023-01-24 Board Of Regents, The University Of Texas System Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
WO2022081522A1 (en) 2020-10-13 2022-04-21 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
KR20240055041A (ko) * 2021-09-01 2024-04-26 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 혼합 계통 키나제 억제제 및 억제제의 사용 방법
CN117447470A (zh) * 2023-02-20 2024-01-26 杭州医学院 一种作为hpk1抑制剂的吡咯并吡啶衍生物、制备方法及其应用
WO2025021997A1 (en) 2023-07-27 2025-01-30 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts New map4k1 inhibitors
WO2025096300A1 (en) * 2023-10-30 2025-05-08 Eli Lilly And Company Novel methods for the preparation of 3-azabicylco[3.1,0]hexane-6-carboxamide derivatives
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
EP0765327B1 (en) 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7220833B2 (en) 2002-12-03 2007-05-22 Thomas Nelson Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EP1663239A4 (en) 2003-09-10 2008-07-23 Cedars Sinai Medical Center KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER
CA2578066C (en) * 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
EA201000113A1 (ru) * 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
WO2009053737A2 (en) * 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
RU2010154473A (ru) 2008-05-30 2012-07-10 Фостер Вилер Энергия Ой (Fi) Способ и устройство для генерации мощности сжиганием обогащенного кислородом топлива
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
BR112012009257A2 (pt) 2009-10-22 2016-11-22 Genentech Inc modulação de degeneração de axônio.
RU2012131373A (ru) * 2009-12-23 2014-01-27 Плексксикон, Инк. Соединения и способы модулирования киназы, а также показания для такого модулирования
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
US8598156B2 (en) * 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
JP2013525476A (ja) * 2010-05-04 2013-06-20 ファイザー・インク Ａｌｋ阻害剤としての複素環式誘導体
AR081039A1 (es) * 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
WO2011149950A2 (en) 2010-05-24 2011-12-01 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
RS55582B1 (sr) * 2011-05-13 2017-06-30 Array Biopharma Inc Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze
CA2871695A1 (en) * 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
PE20161063A1 (es) * 2013-05-01 2016-10-22 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
KR20160002850A (ko) * 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
MX2016008110A (es) * 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.

Also Published As

Publication number Publication date
WO2014111496A1 (en) 2014-07-24
JP6199991B2 (ja) 2017-09-20
US10028942B2 (en) 2018-07-24
EP2945938B1 (en) 2018-03-07
HK1209114A1 (en) 2016-03-24
US20160002228A1 (en) 2016-01-07
CN104918934B (zh) 2017-12-22
TW201434825A (zh) 2014-09-16
CN104918934A (zh) 2015-09-16
KR101701663B1 (ko) 2017-02-01
JP2016505028A (ja) 2016-02-18
BR112015016395A2 (pt) 2017-07-11
US20170087137A1 (en) 2017-03-30
US9550777B2 (en) 2017-01-24
RU2015131314A (ru) 2017-02-27
KR20150108390A (ko) 2015-09-25
MX2015009270A (es) 2015-10-30
EP2945938A1 (en) 2015-11-25
TWI498325B (zh) 2015-09-01
CA2896187A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
AR094502A1 (es) Pirazoles sustituidos en posicion 3 y usos de los mismos
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CL2016000981A1 (es) Formulaciones de estrigolactona y sus usos
CL2016001241A1 (es) Nuevos compuestos pesticidas y usos
IL240845A0 (en) Compounds and uses thereof for the modulation of hemoglobin
EP3804591C0 (en) SKIN CLEANSING DEVICE
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
HUE049637T2 (hu) Toalettben lehúzható katéterek
HRP20170945T1 (hr) Sulfamoil-arilamidi i njihova uporaba kao lijekova za liječenje hepatitisa b
CL2016000777A1 (es) Biomarcadores de cáncer y usos de los mismos
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
BR112016005121A2 (pt) Artigo absorvente
BR112016003758A2 (pt) Artigo absorvente
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
SI3030519T1 (sl) Triciklične benzoksaborolne spojine in njihove uporabe
SMT201600069B (it) Composizioni comprendenti 15-hepe e metodi d’uso delle stesse
HRP20182134T1 (hr) Triazinski spoj i njegova upotreba u medicinske svrhe
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
BR112016007386A2 (pt) derivados alcalinos bicíclicos e usos dos mesmos
PL3331063T3 (pl) Akumulator i zespół akumulatorowy
DK2956471T3 (da) Il-1beta-hæmmersammensætning og anvendelse deraf
BR112016004943A2 (pt) aparelho médico e uso
BR112016027379A2 (pt) formulações tópicas e seus usos
ES2717446T3 (es) Péptidos derivados de ERK y usos de los mismos
HRP20182199T1 (hr) Kruti pripravci koji sadrže tofogliflozin i postupak za njihovu proizvodnju

Legal Events

Date Code Title Description
FB Suspension of granting procedure